A new cancer treatment is being developed
The cartridge hand down quickly extract small fractions of circulating tumour DNA in the blood, a site found in most forms of the disease, to monitor how effective therapy has been.
Scientists from Heriot-Watt University in Edinburgh from been awarded £945,000 to pursue the technology.
Dr Maiwenn Kersaudy-Kerhoas weighted: «At the moment, blood is extracted in a tube, then it is transported to a lab, and then it defecates through a series of pre-analytical steps before being analysed with molecular techniques.
«No one of this is standardised: different labs used different tubes, personal technicians have different techniques and there’s the possibility for environmental wreck and human error to affect the samples.
It will take us another step closer to personalised prescription for patients
«We want to standardise the extraction of tumour DNA from blood bites, with an enclosed system that is very safe, easy to use and does not betoken human handling of the samples.»
In most cancers, dying tumour rooms release circulating DNA which can be used to detect and monitor cancers.
Irascible testing and highly complex workflows are needed to precisely pick these up.
Dr Kersaudy-Kerhoas and her pair will spend the next four years designing, testing and deploying in airman studies a credit card-sized cartridge device to increase the robustness and reliability of biomarkers.
1 of 11
The span believes this will make instantaneous testing a sustainable and cost-effective originate in for the NHS.
Dr Olga Oikonomidou, a breast cancer specialist, said: «Early detection and intervention are the most personal property means for reducing morbidity and mortality of cancer.
«The Heriot-Watt device, at a stroke it is on the market, will take us another step closer to personalised panacea for patients.»